D.E. Shaw & Co
MLTX icon

D.E. Shaw & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

D.E. Shaw & Co’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92,300
Closed -$662K – 4858
2025
Q3 		$662K Buy
+92,300
New +$4.81M ﹤0.01% 3710

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

D.E. Shaw & Co's MLTX Position: Q2 2026 in Review

D.E. Shaw & Co increased its MoonLake Immunotherapeutics (MLTX) stake by 41% in Q2 2026, buying an estimated $17.7M and bringing the position to 3,365,507 shares worth $65.5M. The position accounts for 0.03% of the portfolio, ranked #626.

D.E. Shaw & Co first reported a position in MLTX in Q2 2021 and has held it in 8 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • D.E. Shaw & Co held 3,365,507 shares of MoonLake Immunotherapeutics worth $65.5M as of Q2 2026.
  • D.E. Shaw & Co bought 974,846 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $17.7M.
  • MoonLake Immunotherapeutics made up 0.03% of D.E. Shaw & Co's portfolio in Q2 2026, its #626 holding.
  • D.E. Shaw & Co first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 8 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.